RecruitingPhase 3NCT03067181
Rare condition
Testicular seminomatous germ cell tumor
5
studies recruiting now
as of 7 Sept 2026
40
studies registered in total
as of 7 Sept 2026
10
countries with a recruiting site
as of 7 Sept 2026
21 Oct 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT07218913
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
RecruitingPhase 2NCT05500391
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
RecruitingNot applicableNCT05345158
R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
RecruitingPhase 2NCT06932458
A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Testicular seminomatous germ cell tumor studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Testicular seminomatous germ cell tumor study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Testicular seminomatous germ cell tumor
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (KIT).
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).